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Abstract  
 
Magnolia officinalis-based herbal preparations are used for the treatment of a 
range of different health problems. Magnolia bark contains magnolol, 
metabolized to tetrahydromagnolol (THM), and honokiol, all presenting with both 
cannabimimetic and GABA-ergic activities, hence of possible attraction to 
vulnerable individuals/recreational misusers. Hence, we aimed here at: reviewing 
the literature relating to Magnolia misusing issues; describing, through an 
assessment of related anecdotal online reports, the magnolia possible misusing 
potential; obtaining an overview of Magnolia products’ online acquisition 
possibilities. 
No peer-reviewed papers relating to Magnolia 
abuse/misuse/dependence/addiction were identified. Conversely, from a range of 
websites commenting on Magnolia misuse issues it emerged that there may be 
three groups of Magnolia misusers: a) subjects with a psychiatric history already 
treated with benzodiazepines, being attracted to Magnolia bark as a ‘natural 
sedative’; b) subjects with a polydrug misuse history, ingesting Magnolia with a 
range of other herbs/plants, attracted by the compound GABA-ergic/ 
cannabimimetic activities; c) subjects naive to the misusing drugs’ scenario, 
perceiving Magnolia as a natural dietary supplement or as a weight control 
compound.  
To the best of our knowledge this is the first paper commenting on the possible 
Magnolia derivatives’ potential of misuse. Magnolia’s recent increase in 
popularity, mainly as a sedative, may be arguably due to its peculiar 
pharmacological properties; acceptable affordability levels; virtually worldwide 
favourable legal status; and customers’ attraction to a product being perceived 
as ‘natural’ and hence somehow ‘safe’. Future, potent, synthetic magnolol and 
honokiol structural analogues could however contribute to increasing the number 
of synthetic GABA-ergic/cannabimimetic misusing compounds.  
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Introduction 
Magnolia officinalis is part of the Magnoliaceae family; its bark contains magnolol 
and honokiol (Lee et al., 2012; Watanabe et al, 2002), respectively identified in 
ratios of approximately 4:1 (Kotani et al. 2005; Tsai and Chen, 1992), together 
with α-/β-/γ-eudesmol and methyleugenol (Wrigley, 2009).  
Magnolia bark-containing preparations (Houpo or Koboku; for a thorough review 
of the issue, see Lee et al, 2011; and Wrigley 2009) have a role in both Chinese 
and Japanese traditional herbal medicine (Rempel et al., 2012; Xu et al., 2008), 
reportedly possessing a range of activities, including:  anti-oxidant; anti-
inflammatory/antibacterial; antithrombotic/anti-platelet; hypoglycaemic; smooth 
muscle relaxant (Squires et al, 1999; Sohn et al, 2007); weight control (Garrison 
and Chambliss, 2006); anti-dyspeptic/prokinetic (Oikawa et al. 2005); antiepi-
leptic (Chiou et al., 1997); and hepato-protective (Lee et al., 2012).  
The mechanisms underlying Magnolia compounds’ central pharmacological activi-
ties are not clear (Lee et al, 2011). Magnolol is a partial agonist at both endo-
cannabinoid receptor subtypes (CB1 and CB2); with a higher potency at CB2 (Ki 
1.44 ± 0.10 µM) as opposed to CB1 (Ki 3.15 ± 1.65 µM; Rempel et al, 2012). 
THM, the main faecal magnolol metabolite, is still active both as a full CB1 ago-
nist and as a CB2 partial agonist (e.g. CB1 Ki 2.26 ± 0.89 µM; CB2 Ki 0.416 ± 
00.89 µM) (Rempel et al, 2012). Furthermore, honokiol shows full agonist prop-
erties at CB1 receptors, whilst acting as antagonist/inverse agonist at the CB2 
receptor subtype. Hence, magnolol, honokiol and THM show higher intrinsic ac-
tivity at CB1 than tetrahydrocannabinol/THC, the main cannabis euphoriant com-
pound (Fattore, 2016). Magnolia compounds’ interaction with gamma-
aminobutyric acid-A/GABA-A and muscarinic receptors (Squires et al, 1999; Lin 
et al, 2007) may be consistent with reducing anxiety levels observed in small-
scale clinical studies (Kalman et al., 2008; Mantani et al. 2002). Indeed, in ani-
mal behavioural models honokiol and dihydrohonokiol are described as producing 
anxiolytic, diazepam-like, effects (Alexeev et al, 2012; Kuribara et al, 1998). 
Conversely, the magnolol/honokiol antidepressant-like activities observed in pre-
clinical models may be associated with alterations in serotonin turnover in the 
frontal cortex, striatum and nucleus accumbens (Nakazawa et al, 2003).  
Magnolol and honokiol seem to have similar pharmacokinetic characteristics, with 
half-lives being both almost dose-independent and of first-order (Lee et al, 
2011). Both compounds can readily pass the blood brain barrier (Tsai et al, 
1996; Wang et al, 2011); magnolol oral bioavailability is in the region of 10% 
(Wrigley, 2009) and is extensively metabolized in the liver, with glucuronides 
being its major metabolites. Similarly, glicuronidation and sulphation are the 
main metabolic pathways for honokiol (Bohmdorfer et al, 2011; Hattori et al, 
1986).  
Magnolia derivatives’ could interact with other sedatives, increasing the risk of 
drowsiness/motor reflex depression (Wrigley 2009). Although high-dosage 
magnolol may induce in vitro hepatotoxicity (Kao et al, 2010), acute/long term 
preclinical/clinical toxicity studies have not identified any biological alterations 
associated with Magnolia-based (including mints/gums) preparations’ intake (Liu 
et al., 2007; Wrigley, 2009). However, tremors; peri-labial numbness; sexual and 
thyroid dysfunction; fatigue; and headache have been anecdotally reported by 
small numbers of Magnolia users (Kalman et al 2008).  
Magnolia GABA-ergic and cannabimimetic activities could arguably be of 
attraction to vulnerable individuals/recreational misusers. Hence, we aimed here 
at: reviewing the literature relating to Magnolia compounds’ misusing issues; 
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assessing the Magnolia bark/derivatives’ possible misuse potential whilst 
considering the related anecdotal online reports; and providing an overview of 
the Magnolia online acquisition possibilities from both English- and Italian-
language websites.  
 
Materials and methods 
To identify the peer-reviewed papers commenting on Magnolia misuse issues, a 
comprehensive search on the Embase, Scopus; Google Scholar and 
Pubmed/Medline databases was performed using the following key words: 
(Magnolia) AND (abuse OR misuse OR poisoning OR dependence OR addiction). 
No language or time restrictions were placed on the electronic search; focus was 
on clinical data only and covered the period up to August 9th, 2016.  
To identify information on Magnolia misusers’ first-hand experiences, a 
qualitative/observational approach on selected websites was carried out. In doing 
so, between January 2014 and March 2016 a range of qualitative Google 
searches were carried out, both in English and in Italian, using key words such 
as ‘Magnolia and abuse‘, ‘Magnolia and misuse‘, and ‘Magnolia and experience‘. 
The first 2 pages/20 hits per keyword (e.g. 60 per language; e.g. 120 links) were 
considered. A number of websites were excluded, since: not relevant (e.g. 
referring to Magnolia role in gardening); being duplicates; or requiring a 
registration/payment procedure. Conversely, a range of fora posts/threads 
relating to a few Magnolia themes, including: psychoactive effects; dosage/intake 
modalities; tolerance/withdrawal; untoward effects; and use in combination with 
other psychoactive compounds; were specifically analysed. No posts/other 
contributions to fora discussions were made, and no information or clarification 
of content was sought by the researchers.  
To obtain an overview of Magnolia products’ online purchase possibilities, a range 
of Google searches in English and Italian were carried out, using the ‘Magnolia 
bark to buy’; and ‘Magnolia bark purchase’ key words. The information provided 
by the identified links on: safety; consumer reviews; and purchasing costs were 
analyzed.  
To assess possible increase over time in terms of interest in Magnolia-related 
issues, a range of Google Trends (Google Trends, 2016) searches were here 
carried out. Starting from 2004, this approach shows how often a particular 
search-term is entered across the various regions of the world/various 
languages. The search term queries included: ‘Magnolia’; ‘Magnolia bark’;  
‘Magnolia bark + cannabis’; ‘Magnolia bark + cannabimimetic’; ‘Honokiol’; 
‘Magnolol’; ‘Magnolia + purchase’; ‘Magnolia bark + tranquilizer’; ‘Magnolia bark 
+ antidepressant’; ‘Magnolia bark + euphoria’; and ‘Magnolia bark + misuse’. 
Ethics’ approval for the study was granted by the University of Hertfordshire 
School of Pharmacy Ethics Committee, on December 15th, 2010 (reference code 
PHAEC/10-42), with a further 5-year extension of the approval having been 
granted in November 2013.  
 
Results 
No peer-reviewed papers relating to Magnolia 
abuse/misuse/dependence/addiction were here identified. Conversely, some 41 
websites relating to Magnolia issues were here assessed, with most (e.g. 21) 
being dedicated to its purchase/acquisition. A further 13 websites included 
specific/illustrative comments on the Magnolia compounds’ associated 
psychoactive effects. Analysis of the 137 relating posts identified from here 
showed that in most (e.g. n=133) cases users were commenting on the 
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Magnolia-related anxiolytic/sedative effects, whilst n=4 posts emphasized its 
cannabimimetic/recreational effects. Further reasons to self-administer with 
Magnolia included achievement of antidepressant; analgesic; anti-nausea; and 
weight control effects (see Table 1). Specifically, three groups of Magnolia 
misusers were here tentatively identified: a) subjects with a psychiatric history, 
self-administering with Magnolia as a sleeping aid; as a ‘natural alternative’ to 
prescribing sedatives; or to cope with benzodiazepines’ withdrawal; b) subjects 
with a polydrug misuse history, allegedly ingesting Magnolia to:  
enhance/modulate the effects of cannabimimetic/’Spice’ drugs and/or of other 
GABA-ergic molecules, especially phenibut and gammahydroxybutyrate-GHB. A 
range of herbs/plants, including Mytragina speciosa/’Kratom’, and Sceletium 
tortuosum/’Kanna’;  were here reportedly co-administered with Magnolia (see 
Table 1); c) subjects naive to the misusing drugs’ scenario, perceiving Magnolia 
either as a natural dietary supplement or as an affordable way to lose weight. 
Misuse of magnolia bark compounds mostly seemed to occur orally, with smoking 
and vaporizing intake techniques being also reported, at dosages in the range of 
60-900 mg. Adverse, transient, untoward effects included: mouth/throat 
numbness; lightheadedness/tiredness; and dizziness. Although specific 
withdrawal symptoms were not described, levels of tolerance were anecdotally 
reported (see Table 1).   
A vast range of Magnolia vending websites, especially when searching in English, 
was identified. Branded with various commercial names, Magnolia derivatives 
were offered either as pure concentrates/extracts or mixed with other 
substances. Overall, these commercial websites labelled their products as ‘safe’, 
‘legal’, and ‘pure’, whilst describing themselves as ‘verified merchants’, offering a 
‘100% satisfaction guaranteed/top choice supplement’ deal. Purchase prices 
were in the range of euros 5-55 /USD 6-60 per 60 Magnolia bark extract tablets, 
with variations depending on the quantity of items purchased. 
‘Google Trends’ search queries with the term ‘Magnolia’ have been associated 
with levels of interest since April 2015, especially from: Poland, the US, and the 
Philippines. Conversely, the ‘Magnolia Bark’ searches peaked in 2004 and 2013, 
whilst the ‘Magnolia purchase’ related searches have remained stable since 2004. 
The ‘Magnolia bark + tranquilizer’; ‘Magnolia bark + antidepressant’; and 
‘Magnolia bark + misuse’ searches have been associated with levels of interest 
both in 2012-3 and since February 2016, mostly from the US regions. Finally, 
only minimal levels of interest were here observed when the search term 
‘Magnolia bark’ was associated with ‘cannabis’; cannabimimetic’; and ‘euphoria’. 
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Table 1: Misuse of magnolia bark extract; online users’ accounts and illustrative examples of 
English and Italian vending websites  
 Sought effects 
Reduction of anxiety levels ‘... magnolia bark extract ... has all the anti-anxiety effects of a benzo, minus the impairment in motor skills ...’ (Drugs-forum.com) 
‘….Non-sedating, non-euphoria anxiety relief. Best alternative I've found to asking a doctor for a pill for your anxiety….’ 
(Amazon.com) 
Sleeping aid ‘... herbal alternatives to benzos for sleep?...’ (herbwisdom.com) 
‘……apparently it is very similar to a light benzo dose....’ (Bluelight.org) 
‘…I have suffered from insomnia for many years and have used quite a few prescription medications…all have given me 
a morning hang over effect…. For several months now, I have been taking one Magnolia bark capsule to help me fall 
back to sleep, and I am very pleased with the results…..’ (Amazon.com) 
 Mild antidepressant-effect ‘... magnolia bark extract ... it helps the mood also ...’ (Amazon.com) 
To ‘chill out’; alone or in 
association with alcohol 
‘... couple scoops of magnolia bark extract after work are perfect for chilling for the rest of the evening ...’ (Amazon.com) 
‘…real good with a few beers, especially at the end of a long day …’ 
 To use as a safer alternative of 
phenibut 
‘... I had heard great things about phenibut for social anxiety, but not-so-great things about withdrawal/ dependance, and I needed 
something mild enough that I could take it at work or driving without looking or feeling ‘on something’. So I settled on this magnolia 
bark extract, and like many of the other reviewers find it effective ...’ (Amazon.com) 
‘….I purchased this product to use as a supplement to phenibut, as you can not use phenibut often without risks …. 
phenibut can be a little too strong sometimes……Magnolia bark fits those needs for me…..’ (Amazon.com) 
 
To taper off/to lighten the 
withdrawal effects of 
benzodiazepines, phenibut, 
tobacco, alcohol, GBL, 
opiates 
‘... honokiol ... very useful for benzo addicts trying to taper ...’ (Bluelight.org) 
To control appetite/weight  ‘... magnolia bark extract ... seem to work for appetite control quite well. Days when I took Magnolia Bark, I’d often forget to eat. It 
wasn’t that I couldn’t eat or genuinely didn’t want to. It was that it just didn’t really occur to me.When it would occur to me, I’d go 
“yeah, I guess I am kind of hungry” and grab something. But I wouldn’t overeat, even though I hadn’t eaten in twelve hours ...’ 
(herbwisdom.com)) 
‘…I tried Magnolia Bark Extract to help relieve stress and to stop the cortisol from creating belly fat…’ 
(herbwisdom.com) 
To relieve nausea ‘... magnolia bark extract ... excellent product great for relieving nausea too! ...’ (Amazon.com) 
To use as a relief from 
headaches 
‘... honokiol ... is often helping me out with tension headaches especially ...’ (entheogen-network.com) 
 Prescribing medicines/recreational drugs/herbs and plants reportedly taken in 
combination with Magnolia-related compounds 
Use in concomitance with:   
• GABAergics: 
phenibut; 
zolpidem;  
• THC-like 
molecules: 
THC; synthetic 
cannabimimeti
cs;  
• Cognitive 
enhancers 
• Herbs/plants: 
Mytragina 
speciosa/krato
m; Erythrina 
mulungu/Mulu
ngu; Bacopa; 
Sceletium 
tortuosum/Kan
na; Rhodiola 
rosea; and 
Ashwaghanda 
‘... 2-4 capsules Magnolia bark ... can double the effects of phenibut (truly, i have tried this with others and they agree).They 
quoted 2 to 5 times potentiation i think. My brother said he noticed a 75% increase, for me it is a doubling effect ...’ 
(forum.mindandmuscle.net) 
‘….Magnolia Bark Extract works well for relaxation purposes. I would try the Magnolia Bark Extract on its own before 
adding it to Ambien (e.g. zolpidem) + Kratom, because the effect could be strongly synergistic…’ (Drugs-forum.com) 
‘….It felt kind of like a muscle relaxer when I smoked cannabis….I took about 10mg and placed it over a bowl of 
cannabis (Michiganmedicalmarijuana.org) 
‘... SWIM would imagine that with Spice Tropical Synergy the honokiol and magnolol in the magnolia bark synergises with the effects 
of the JWH-018 too ...’ (Drugs-forum.com) 
‘…..I found it to be an especially good adjunct for using with cognitive enhancers, like hydergine or lucidril, as it seemed 
to balance out their stimulating properties….’ (Amazon.com) 
‘….ashwaghanda and magnolia i find to be good and not causing any extra anxiety or withdrawal problems. ….Anyway I 
recently ordered some magnolia bark along with some 98% honokiol extract and I'm gonna mix the two….. Also ordered 
Mulungu which Ive heard good things about, possibly Kanna though I'm a bit weary of kanna since it might have ssri 
action and I seem to be sensitive to that. I agree with who ever said mixing some bacopa and rhodiola together, as I've had 
some good results mixing this with the magnolia and ashwaghanda. ….’ (Longecity.org) 
‘…..is very effective for reducing Kratom's nausea….’ (Drugs-forum.com) 
 
 Experience reports 
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 ‘… 8:30pm - Swim put the 50mg of isolate in a glass of water and drank. 
9:02pm - Swim noticed a little something in the back of his mind which can only be described as a flash of complete tiredness/pure 
disreguard for my surroundings (this could have been placebo effect, not sure it was very short in duration, maybe  10-20secs) 
9:17pm - What was once a flash is now steady. Swim says he feels relaxed and at the same time he feels a disreguard for his surrounding or 
anything that may have been troubling him in the day. 
9:37pm - Peak was reached, Swim said he still feels relaxed but the feeling of disreguard has subsided slightly. 9:45pm - Swim decided to 
does with another 50mg of isolate. 
10:22pm - Swim once again slightly feels disreguard for surroundings. 
10:53pm - Swim feels like some of his everyday problems seem to not matter as much. Things just seem trivial that might normal 
bother swim. Swims tiredness has increased. Swim feels that the possibility for anxiety are pretty much slim to none no matter what my 
have come his way. Swim also notices a very slight feeling of warmth that can be associated with warm opiate blankets, however ; in 
this case it just feels more relaxing instead of euphoric (again it is subtle, but its there). 
11:20pm - Swim still feels effects and is still tired. Swim says he must go to bed. Summary: 
Although swim doesn't suffer from anxiety the occasional day does presents itself. Swim will deffinately keep this in his toolbelt for 
future use against anxiety. Swim also feels that in just 50mg dosages this could deffinately be used as tool  to relax at the end of  the day  
before bed  to take  the edge off.    Swim  just  wonders  if  plain  bark  powder  could  be utilized in the same way and in what 
dosages of powder would be taken …’ (Entheogen-network.com) 
 Intake modalities; dosages; and side effects  
Ingestion routes; dosages 
advised 
 ‘……i take about 600mg to 800mg at a time, any less doesn't do much….’ (Amazon.com)  
‘…not to be taken sublingually…’ (Amazon.com) 
‘….i use it with Coconut Milk (source of fat for enhanced absorption) and its pretty tasty as long as only using a small 
amount…… I have tried using Magnolia Bark Extract sublingually at approximately 200mg…. it killed the taste buds on 
the front half of my tongue. I could no longer taste even pure salt. It tasted like beach sand…..’ (Drugs-forum.com) 
Withdrawal; tolerance; side 
effects 
‘….magnolia i find to be good and not causing any extra anxiety or withdrawal problems….’ (Longecity.org) 
‘…One thing I did notice about magnolia bark extract  is if you take it two days in a row , the second day isn´t as good as 
the first day…’ (Drugs-forum.com) 
” ….The only problem with the extract, for me at least, is that it starts to loss some of its magic with frequent use, so I just 
use it one or twice a week ‘…(Amazon.com) 
‘.I have recently tried Lift Mode Magnolia bark powder - put in hot water and drank. It caused entire mouth and throat to 
go numb; then next day became extremely sore as though burnt….’ (Webmd.com) 
‘……..I was taking 200mg for 8 days and developed vertigo one morning. After about a week the vertigo seems to have 
stopped, but I still have a mild ringing in the ears and feel light headed at times….’ (herbwisdom.com) 
 
  Illustrative examples of English/Italian language websites allegedly offering 
Magnolia bark extract for purchase 
 
 
 English language 
http://www.ebay.co.uk/ 
AllStarHealth.com  
http://www.nutricargo.com/ 
www.amazon.com 
http://www.amazon.co.uk/ 
http://www.puritan.com/ 
http://www.vitacost.com/ 
www.healthmonthly.co.uk 
http://www.swansonvitamins.com/ 
http://www.walgreens.com/ 
http://vitaminsbecause.biz/ 
http://www.zoya.bg/ 
http://www.super-smart.eu/ 
http://www.iherb.com/ 
http://hawaii-pharm.com/ 
etc 
 
Italian language 
http://www.biovea.com/ 
http://www.supersmart.com/ 
http://www.ebay.it/ 
http://it.made-in-china.com/ 
http://www.fedelfarma.com/ 
www.vitaminity.com 
etc 
 Note: SWIM: somebody who is not me. Spelling mistakes have not been edited, but 
rude words have been deleted. Most data collected from online forums that could be 
seen as personal identifiable (e.g. usernames, complete URLs for specific threads etc) 
were here anonymized. The online users’ accounts here reported were selected on 
the basis of being considered particularly illustrative of the clinical issue anecdotally 
described. 
 
Discussion and Conclusions 
To the best of our knowledge this constitutes the first description of the Magnolia 
derivatives’ putative potential of misuse. The compound may be misused mainly 
as a sedative/sleeping aid, but polydrug intake patterns were here identified as 
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well. Furthermore, synthetic magnolol and honokiol structural analogues could 
contribute to increasing the number of synthetic cannabimimetic/GABA-ergic 
misusing compounds.  
The web plays a huge role in the modification of both psychotropics’ availability 
and changes in drug scenarios (Schifano et al, 2015; 2016), and one could argue 
that the vast levels of Magnolia online acquisition possibilities may reflect the 
large number of potential customers. Indeed, the recent increase of Magnolia 
popularity, mainly a sedative, here identified may arguably be due to its peculiar 
pharmacological properties; acceptable affordability levels; virtually worldwide 
favourable legal status; and customers’ attraction to a product being perceived 
as ‘natural’ and hence somehow ‘safe’.   
The pharmacological effects of magnolol, THM, honokiol, and 4-O-methylhonokiol 
might be used as a new generation of anti-abstinence, anti-craving and 
neuroprotective drugs, with their GABA-ergic activity possibly being useful as 
well for the treatment of convulsions, spasms, and associated pain (Coppola and 
Mondola, 2014). Conversely, in considering magnolol/THM cannabimimetic 
properties, recent work has shown that is possible to design and synthesize a 
series of (TH)magnolol analogues with extremely high CB1 receptor affinity, 
selectivity, efficacy, and potency (Fuchs et al, 2013. Indeed, this is the case of 
the dual CB1/CB2 full agonist 2-(2-methoxy-5-propyl-phenyl)-4-hexylphenol (Ki 
CB1∶	0.00957 µM; Ki CB2∶	0.0238 µM; Fuchs et al, 2013). To put things into 
perspective, THC displays a modest affinity (Ki: 35-80 nmol) at the CB1 receptor, 
whilst AM-694, the highest affinity molecule within the synthetic cannabimimetic 
group (SC; ‘Spice’; ‘K2’) displays a Ki: 0.1 nmol (Fattore, 2016). Indeed, SC 
(Schifano et al 2015; 2016) intake has been associated with a number of 
psychopathological/psychotic manifestations (e.g. ‘spiceophrenia’; Papanti et al, 
2014). Apart from their CB1-agonist activities, further honokiol/magnolol 
analogues present with very potent GABA-A receptor allosteric modulators 
(Fuchs et al, 2014), hence defining a new GABA-ergic/cannabimimetic 
psychotropics’ class. 
There are a number of possible limitations of the present study; a multi-lingual 
analysis of a larger sample of websites could have provided better levels of 
information. Furthermore, only publicly available web sites/fora were monitored 
here, and further data of interest could possibly have been identified by the 
analysis of the ‘deep web’/’dark net’ material (Orsolini et al, 2015). We made no 
Magnolia purchase attempts, hence one could argue about the product 
content/dosage being delivered. Overall, anecdotal reports are only partially 
reliable and it may be inappropriate to trust information obtained from the 
internet without independent verification. Since no peer reviewed papers relating 
to Magnolia misuse issues were identified, the present conclusions mainly relied 
on sources (e.g. web sites) characterized by levels of unreliability. Hence, a bias 
may well have been introduced here, and the manuscript’s conclusions should be 
considered as Authors’ opinions. Only large scale, adequately controlled, clinical 
studies can give a clear indication of a drug characteristics and adverse effects. 
However, in line with present observations, previous studies from our group 
(Schifano et al, 2009; Siemann et al, 2006) have clearly suggested that the 
increase in online trafficking/debate about a specific psychoactive drug typically 
precedes the occurrence of clinical incidents at the population level.  
The issue of Magnolia products’ misuse may be a reason for concern; consumers 
may not be made fully aware of the pharmacological activity, and possible 
medical consequences, of the compound(s) they are ingesting. Furthermore, 
Magnolia products’ misuse may often occur in the context of polydrug intake, and 
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the pharmacodynamics/pharmacokinetics’ interactions of magnolol/THM/honokiol 
with other substances are not known.  
As with any centrally active drug, physicians should carefully evaluate patients 
for history of drug abuse and observe them for signs any products’, including 
Magnolia bark, misuse. 
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